Fig. 2

SH-11037 significantly inhibits ocular developmental angiogenesis in zebrafish larvae.

(a) Representative epi-fluorescence images of hyaloid vessel (HV) morphology on lenses dissected from drug-treated 5 days post fertilisation (dpf) Tg(fli1:EGFP) larvae. A significant reduction in primary HV branch number is observed at 10 µM SH-11037 (white arrows), scale bars = 50 µm. (b) Representative bright-field images of 5 dpf larval morphology following SH-11037 treatment. Some larvae treated with 10 µM SH-11037 demonstrated pericardial and yolk sac oedema. Scale bars = 500 µm. (c) Quantification of the dose-dependent inhibition of primary HV development in 5 dpf Tg(fli1:EGFP) larvae treated from 2 dpf with 1-10 µM SH-11037. (d) Quantification of the dose-dependent inhibition of SH-11037 on number of hyaloid vessel branches in treated larvae compared to DMSO control. Up to a 40% reduction in primary HV and vessel branches is observed in response to 10 µM SH-11037. ***P <0.01, ***P < 0.001, one-way ANOVA with Dunnett?s post hoc tests. Mean ± s.e.m., n ≥ 3.